Literature DB >> 8912209

Mutation rates in LTR of HTLV-1 in HAM/TSP patients and the carriers are similarly high to Tax/Rex-coding sequence.

M Saito1, Y Furukawa, R Kubota, K Usuku, S Izumo, M Osame, M Yoshida.   

Abstract

The genomic sequence of human T-cell leukemia virus type 1 (HTLV-1) is highly conserved, although minor sequence variations enable classification of the isolates into several subgroups. We previously reported, however, that the Tax-coding sequence of HTLV-1 genome is highly variable in a random fashion within individuals with HAM/TSP and asymptomatic carriers. Here, we describe frequent base substitutions in the LTR sequence similarly to those in Tax-coding sequence. These observations indicate that frequent mutations are not unique to the sequence encoding the most effective antigen for cytotoxic T lymphocytes, but also seen in the LTR, a non-coding sequence. Thus, frequent mutations seem to occur during the viral replication process rather than the selection of rare mutants by immune surveillance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8912209     DOI: 10.3109/13550289609146897

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  2 in total

1.  HTLV-1 propels untransformed CD4 lymphocytes into the cell cycle while protecting CD8 cells from death.

Authors:  David Sibon; Anne-Sophie Gabet; Marc Zandecki; Christiane Pinatel; Julien Thête; Marie-Hélène Delfau-Larue; Samira Rabaaoui; Antoine Gessain; Olivier Gout; Steven Jacobson; Franck Mortreux; Eric Wattel
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

2.  Tax gene expression and cell cycling but not cell death are selected during HTLV-1 infection in vivo.

Authors:  Linda Zane; David Sibon; Lionel Jeannin; Marc Zandecki; Marie-Hélène Delfau-Larue; Antoine Gessain; Olivier Gout; Christiane Pinatel; Agnès Lançon; Franck Mortreux; Eric Wattel
Journal:  Retrovirology       Date:  2010-03-11       Impact factor: 4.602

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.